CEO Michel Vanbrabant will present positive outcomes for iSTAR Medical’s MIGS device MINIjectTM in over 130 glaucoma patients at the Ophthalmology Futures Forum today.
Session: Company Presentations 3
Time: 18:20 – 19:20
The data recently announced by the company showed consistently positive safety and efficacy outcomes in a larger patient population from ongoing trials. The pooled analysis reviewed data from over 130 patients implanted with MINIject into the supraciliary space in stand-alone procedures across 11 trial sites in Europe, the Americas and Asia.
The very promising efficacy, safety and longer-term results in the supraciliary space to date boost confidence in MINIject’s potential to revolutionise treatment for patients with glaucoma.
, Vanbrabant commented.
Ophthalmology Futures Forums are clinician-driven innovation meetings in the ophthalmic healthcare sector. They cover all aspects of global innovation in ophthalmic devices, diagnostics and pharmaceuticals by connecting scientists, physicians, regulators, reimbursement specialists, corporate leaders, venture capitalists and other investors who support the advancement of eye care.
